You nominated and our expert judging panels deliberated – and now, we proudly showcase this diversity of talent in The Pathologist’s 2020 Power List.
George Vasmatzis and John Cheville
Newly discovered genetic alterations could indicate whether treatment or active surveillance is the best option for low-risk prostate cancer patients
Luxembourg’s new molecular diagnostics program aims to establish the value of such analyses as a part of routine cancer care
Lisa M. Wright
To harness liquid biopsy’s many advantages, it’s vital to ensure appropriate testing – and cfDNA synthetic plasma reference standards can help
The spatial arrangement of immune cells could predict whether aggressive chemotherapy is the best option for patients with early-stage lung cancer
An electronic gas-sensing capsule may increase diagnostic and monitoring accuracy in disorders of the digestive tract
Niamh Buckley, Laura Feeney, James Beirne, and Paul Mullan
Markers such as DNA methylation, analyzed by liquid biopsy, may improve on ovarian cancer testing options like gold standard CA125
A collaboration between industry, academia, and the clinic could lead to more efficient, more personalized cancer diagnosis and treatment
New biomarker sensing technology can detect miniscule concentrations of molecules in the blood to assist with patient monitoring
Epigenetics may combine with liquid biopsy to offer an effective way of detecting early-stage cancers and recurrences
With antimicrobial resistance an ever-increasing threat to modern medicine, a new breakthrough may rapidly identify drug-resistant microbe strains to ensure effective treatment
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.